Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: indicative (22), suggestive (83)

AtezolizumabSC Bevacizumab Carboplatin Paclitaxel

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) ATEZOLIZUMAB-SC-BEVACIZUMAB-CARBOPLATIN (AUC6)-PACLITAXEL Regimen • Lung-Atezolizumab-SC-Bevacizumab-Carbopl
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/AtezolizumabSC-Bevacizumab-Carboplatin-Paclitaxel-Ver1.0.pdf

Atezolizumab-Bevacizumab-Carboplatin(AUC6)-Paclitaxel

Description: Chemotherapy Protocol LUNG CANCER ATEZOLIZUMAB-BEVACIZUMAB-CARBOPLATIN (AUC6)-PACLITAXEL Regimen  Lung-Atezolizumab-Bevacizumab-Carboplatin (AUC6)-Paclitaxel Indicati
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Atezolizumab-Bevacizumab-CarboplatinAUC6-Paclitaxel.pdf

Atezolizumab-Bevacizumab

Description: Chemotherapy Protocol Hepatocellular Cancer ATEZOLIZUMAB-BEVACIZUMAB Regimen  HCC-Atezolizumab-Bevacizumab Indication  Atezolizumab in combination with beva
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Atezolizumab-Bevacizumab.pdf

Enhertu (trastuzumab deruxtecan)

Description: Chemotherapy Protocol BREAST CANCER ENHERTU (trastuzumab deruxtecan) ENHERTU is NOT the same drug as Kadcyla (trastuzumab emtansine) or
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Enhertu-trastuzumab-deruxtecan.pdf

DH IVIg approved indications full guidance July 2011

Description: DH INFORMATION READER BOX Policy HR / Workforce Management Planning / Clinical Performance Document Purpose Gateway Referen
Url: /Media/SUHTExtranet/TrustMedicinesFormulary/Forms/DH-IVIg-approved-indications-Full-Guidance-July-2011.pdf

Ipilimumab(1mg/kg)-Nivolumab(3mg/kg)

Description: Chemotherapy Protocol RENAL CANCER IPILIMUMAB (1mg/kg)-NIVOLUMAB(3mg/kg) Regimen • Renal – Ipilimumab (1mg/kg)-Nivolumab (3mg
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Ipilimumab1mgkg-Nivolumab3mgkg.pdf

Atezolizumab

Description: Chemotherapy Protocol LUNG CANCER Atezolizumab Regimen • Lung – Atezolizumab Indication • Atezolizumab is indicated for treating previously platinum-tr
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Atezolizumab.pdf

Atezolizumab

Description: Chemotherapy Protocol GENITOURINARY CANCER Atezolizumab Regimen • Bladder – Atezolizumab Indication • The treatment of adult patients with locally advance
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Atezolizumab.pdf

Ipilimumab Ver 1

Description: Chemotherapy Protocol SKIN CANCER IPILIMUMAB Regimen Skin – Ipilimumab Indication Ipilimumab is recommended, within its marketing authorisation, as an opti
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinIpilimumabVer1.pdf

Bevacizumab ver 1

Description: Chemotherapy Protocol CNS CANCER BEVACIZUMAB This protocol may require funding. This is an unlicensed indication for bevacizumab. Regimen CNS-Bevaciz
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CNS/Bevacizumab-ver-1.pdf

1 to 10 of 527

Previous 1 2 3 4 5 … Next